Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes.
Adult
Advanced Oxidation Protein Products
Anti-Inflammatory Agents
/ pharmacology
Antioxidants
/ therapeutic use
Benzhydryl Compounds
Diabetes Mellitus, Type 1
/ drug therapy
Glucosides
Glutathione Peroxidase
Humans
Hypoglycemic Agents
/ pharmacology
Interleukin-6
Metformin
/ therapeutic use
Middle Aged
Superoxide Dismutase
Journal
Journal of diabetes research
ISSN: 2314-6753
Titre abrégé: J Diabetes Res
Pays: England
ID NLM: 101605237
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
01
2022
revised:
10
04
2022
accepted:
21
04
2022
entrez:
27
5
2022
pubmed:
28
5
2022
medline:
31
5
2022
Statut:
epublish
Résumé
40 individuals with type 1 diabetes (average age of 44.7 ± 2.5 years) were randomized into four groups: (1) control (placebo), (2) empagliflozin 25 mg daily, (3) metformin 2000 mg daily, and (4) empagliflozin-metformin combination (25 mg and 2000 mg daily, respectively). At inclusion and after 12 weeks of treatment, the blood samples were collected, and the oxidative stress (total antioxidative status (TAS), superoxide dismutase (SOD), glutathione peroxidase (GPx), uric acid, advanced oxidation protein products (AOPP), advanced glycosylation end products ((AGE) and isoprostane), and inflammation (C-reactive protein (CRP) and interleukin-6 (IL-6)) parameters were determined. The empagliflozin-metformin combination increased levels of the antioxidants (TAS, SOD, and GPx up to 1.1-fold; Empagliflozin-metformin combination has strong antioxidative and anti-inflammatory capacity, in adults with type 1 diabetes that is greater than that for the individual drugs. Its antioxidative activity at least partially explains the improvement in arterial function. Therefore, it appears that the combination provides the most powerful vascular protection.
Identifiants
pubmed: 35620570
doi: 10.1155/2022/6796470
pmc: PMC9130013
doi:
Substances chimiques
Advanced Oxidation Protein Products
0
Anti-Inflammatory Agents
0
Antioxidants
0
Benzhydryl Compounds
0
Glucosides
0
Hypoglycemic Agents
0
Interleukin-6
0
Metformin
9100L32L2N
Glutathione Peroxidase
EC 1.11.1.9
Superoxide Dismutase
EC 1.15.1.1
empagliflozin
HDC1R2M35U
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
6796470Informations de copyright
Copyright © 2022 Miodrag Janić et al.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Diabetes Care. 2022 Jan 1;45(Suppl 1):S144-S174
pubmed: 34964815
JAMA. 2019 Oct 1;322(13):1312
pubmed: 31573630
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Diabetes Ther. 2020 Sep;11(9):1947-1963
pubmed: 32715425
Diabetes Care. 2022 Mar 1;45(3):650-658
pubmed: 35061022
Theranostics. 2021 Mar 4;11(9):4502-4515
pubmed: 33754074
J Am Coll Cardiol. 2020 Sep 1;76(9):1117-1145
pubmed: 32771263
Theranostics. 2021 Sep 9;11(19):9376-9396
pubmed: 34646376
J Diabetes Sci Technol. 2016 Aug 22;10(5):1059-64
pubmed: 26956240
Int J Mol Sci. 2021 Jun 03;22(11):
pubmed: 34205045
Cardiovasc Diabetol. 2018 Dec 3;17(1):153
pubmed: 30509271
Biomedicines. 2021 Sep 29;9(10):
pubmed: 34680473
Biomedicines. 2020 Dec 22;9(1):
pubmed: 33375185
Mol Metab. 2021 Dec;54:101337
pubmed: 34500107
Metabolism. 2022 Feb;127:154936
pubmed: 34801581
Biomed Pharmacother. 2022 Feb;146:112515
pubmed: 34896968
Biomedicines. 2021 Jul 28;9(8):
pubmed: 34440108
Cell Metab. 2013 Jan 8;17(1):20-33
pubmed: 23312281
Antioxidants (Basel). 2021 Jul 30;10(8):
pubmed: 34439476
Oxid Med Cell Longev. 2017;2017:8416763
pubmed: 28819546
J Clin Med. 2019 Nov 01;8(11):
pubmed: 31683785
Cardiovasc Diabetol. 2020 Sep 22;19(1):143
pubmed: 32962704
Cardiovasc Diabetol. 2021 Jul 16;20(1):145
pubmed: 34271948
Int J Clin Pharmacol Ther. 2021 Jan;59(1):17-25
pubmed: 33094728
Inflammopharmacology. 2021 Apr;29(2):573-576
pubmed: 33728540
Diabetes Obes Metab. 2013 May;15(5):427-31
pubmed: 23167274
Diabetes Care. 2021 Jan;44(Suppl 1):S111-S124
pubmed: 33298420
Front Pharmacol. 2021 Nov 15;12:777083
pubmed: 34867407
Cell Physiol Biochem. 2019;53(5):865-886
pubmed: 31724838